ONCOLYTICS BIOTECH INC — Form 8-K
Filed August 18, 2026 · analyzed by the 8-K Agent
8-K
▲ Likely positive
significance 72/100
What the filing says
Oncolytics received written FDA feedback supporting a two-part regulatory pathway for REO 033, a Phase 2 study of pelareorep in second-line RAS-mutant MSS metastatic colorectal cancer (n=60 Part A). FDA confirmed potential accelerated approval based on objective response rate, with progression-free survival supporting full approval. The company plans to launch Part B expansion upon positive Part A interim data and will pursue an End-of-Phase meeting with the FDA.
Why this rating
FDA alignment on registrational pathway materially de-risks lead program for $72M biotech; accelerated approval potential shortens timeline and reduces pivotal trial cost burden.
See more from August 18, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.